To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Accelerated Breast Irradiation Reduces Breast Cancer Recurrence in 4-Year Follow-Up: Presented at ASBS URL: http://www.pslgroup.com/dg/220EBE.htm Doctor's Guide May 9, 2008
By Carole Bullock NEW YORK -- May 9, 2008 -- Locoregional control, complications, and cosmesis from targeted accelerated partial breast irradiation (APBI) are acceptable and comparable to other forms of APBI, investigators reported here at the 9th Annual Meeting of the American Society of Breast Surgeons (ASBS). The study was designed to evaluate the oncological and cosmetic outcomes achieved with APBI in early-stage breast cancer patients, explained lead investigator Jonathan Nelson, MD, Fellow, Breast Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. In a 4-year follow-up to the MammoSite Brachytherapy Trial, Dr. Nelson and colleagues evaluated 1,449 women with early-stage breast cancer -- 1,260 women with invasive cancer and 188 with ductal carcinoma in situ. All the women were undergoing breast conserving therapy and were enrolled in the ASBS registry. The women received adjuvant APBI at a dose of 34 Gy in fractions of 3.4 Gy. The 3-year actuarial rate of ipsilateral breast tumour recurrence was 2.16%, and the 3-year actuarial rate of axillary failure was 0.62%, Dr. Nelson said during his presentation on May 3. Among 400 women in an extended follow-up (median 41.4 months), the 4-year actuarial rates were 2.16% and 0.87%, respectively. Complication rates for the entire group of 1,449 women included infection in 9.5%, seroma in 26.8%, and fat necrosis in 2.0%. Good/excellent cosmetic results were observed in 95% of women at 12 months, 94% of women at 24 months, in 93% of women at 36 months, and 95% of women at 48 months. This study enrolled a very select patient population with limited follow-up, Dr. Nelson noted in an interview and added that these data are not applicable to all breast cancer patients. "Its use should be determined by the comfort level of both the patient and physician with the limited follow-up. Prospective, randomised trials are needed to further evaluate accelerated partial breast irradiation," he added. The study was initiated by Hologic, Inc., which manufactures the MammoSite radiation therapy system; the ASBS took over the study in 2003. [Presentation title: A Four-Year Clinical Update From the American Society of Breast Surgeons MammoSite Brachytherapy Trial. Oral Presentation.] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.